BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04
Published October 18, 2023 · Recall initiated: September 25, 2023
Summary
FDA records drug Class I recall D-0042-2024, published October 18, 2023 and initiated September 25, 2023. Recalling firm: Scynexis, Inc.; Status: Completed; Reported quantity: 17,376; Lot: Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Scynexis, Inc.
- Distributor
- Nationwide in the US.
- Lot
- Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDALuLu Chinese Express Korean Noodles (Japchae) w/ Vegetables. Net Wt 16oz.October 18, 2023
- FDALittleOak Natural Goat Milk Infant Formula (Stage 1); packaged in 800g (1.8lbs) tin cans - six cans per case.October 18, 2023
- FDALittleOak Natural Goat Milk Follow On Infant Formula (Stage 2); packaged in 800g (1.8lbs) tin cans - six cansOctober 18, 2023
- FDAIncisive CT, software version 5.0October 11, 2023
- FDAGS0008 2Y - Burn Pack - STL, Item Number 880082025October 11, 2023
- FDACitrine Triple Quad Mass Spectrometer, Part Number 5063684October 11, 2023
Questions about this recall
Was BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04 recalled?
Yes. FDA published recall D-0042-2024 on October 18, 2023. Reported hazard: Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail